Anupam Rama analyst JPMORGAN

Currently out of the existing stock ratings of Anupam Rama, 202 are a BUY (69.42%), 63 are a HOLD (21.65%), 26 are a SELL (8.93%).

Anupam Rama

Work Performance Price Targets & Ratings Chart

Analyst Anupam Rama works at JPMORGAN with a stock forecast success ratio of 43.47% fulfilled within 173.62 days on average.

Anupam Rama’s has documented 563 price targets and ratings displayed on 56 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CTMX, CytomX Therapeutics at 22-Apr-2024.

Wall Street Analyst Anupam Rama

Analyst best performing recommendations are on VERA (VERA THERAPEUTICS).
The best stock recommendation documented was for VERA (VERA THERAPEUTICS) at 1/22/2024. The price target of $25 was fulfilled within 3 days with a profit of $8.7 (53.37%) receiving and performance score of 177.91.

Average potential price target upside

AGIO Agios Pharm ALNY Alnylam Pharmaceuticals ALVR Allovir  ALXN Alexion Pharmaceuticals ANAB AnaptysBio APLS Apellis Pharmaceuticals ATRA Atara Biotherapeutics BBIO BridgeBio Pharma BCAB Bioatla  CCXI ChemoCentryx CNST Constellation Pharmaceuticals DVAX Dynavax Technologies EIDX Eidos Therapeutics FOLD Amicus Therapeutics FREQ Frequency Therapeutics GTHX G1 Therapeutics INFI Infinity Pharmaceuticals MRTX Mirati Ther MYOK MyoKardia NBIX Neurocrine Biosciences ORTX Orchard Therapeutics PLC OTIC Otonomy OYST Oyster Point Pharma PASG Passage Bio PTGX Protagonist Therapeutics RIGL Rigel Pharmaceuticals SRPT Sarepta Therapeutics SWTX SpringWorks Therapeutics TBPH Theravance Biopharma VIR Vir Biotechnology ZLAB Zai Lab Ltd CTMX CytomX Therapeutics GBIO Generation Bio Co IRWD Ironwood Pharmaceuticals KNSA Kiniksa Pharmaceuticals Ltd KOD Kodiak Sciences ELEV Elevation Oncology PTCT PTC Therapeutics CYTK Cytokinetics LJPC La Jolla Pharmaceutical Co RAPT RAPT Therapeutics VERA Vera Therapeutics CYT Cyteir Therapeutics ORIC Oric Pharmaceuticals  REPL Replimune Group SLDB Solid Biosciences LLC SNDX Syndax Pharmaceuticals AGLE Aeglea Bio Therapeutics ANNX Annexon  IDYA Ideaya Biosciences RARE Ultragenyx NUVL Nuvalent RLYB Rallybio Corp OLMA Olema Pharmaceuticals SAGE Sage Therapeutic COGT Cogent Biosciences

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

30

$-1.67 (-5.27%)

32

2 months 3 days ago

3/3 (100%)

$-2.99 (-9.06%)

224

Hold

28

$-3.67 (-11.59%)

32

5 months 23 days ago

6/6 (100%)

$5.51 (24.50%)

192

Buy

42

$10.33 (32.62%)

67

9 months 30 days ago

5/12 (41.67%)

$13.87 (49.31%)

213

Buy

38

$6.33 (19.99%)

40

9 months 30 days ago

0/4 (0%)

$9.87 (35.09%)

Buy

37

$5.33 (16.83%)

33

1 years 8 months 21 days ago

6/11 (54.55%)

$7.26 (24.41%)

69

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Anupam Rama is most bullish on?

Potential upside of $52.75 has been obtained for SRPT (SAREPTA THERAPEUTICS)

Which stock is Anupam Rama is most reserved on?

Potential downside of -$14.95 has been obtained for VERA (VERA THERAPEUTICS)

What Year was the first public recommendation made by Anupam Rama?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?